Intellia propels into 2024 with CRISPR pipeline updates

Intellia Therapeutics announced its clinical goals for the next few years, pushing development for its late-stage ATTR asset.

Related Posts

TLM-101 by Therillume for Neurofibromatoses Type I (Von...

Nov 6, 2023

Panama updates their medicine regulatory system

Mar 1, 2024

Enzalutamide by Pfizer for Peritoneal Cancer: Likelihoo...

Dec 24, 2023